Get the latest tech news
Antibody Drug Conjugates: A frontier in cancer treatment
An in-depth look at Antibody Drug Conjugates (ADCs), a groundbreaking innovation that has significantly expanded treatment possibilities for many cancer patients.
This has all led us to the turn of another century and another scientific age: the birth of personalized medicine, driven by advances in computation, engineering, and our understanding of complex processes within the human body. Sometimes, the incremental improvements over the existing standard of care can seem unremarkable–a small increase in response percentage for a subset of patients of a certain cancer type and treatment history, or a modest average gain of months of stable disease before the tumor grows again. While it’s hard to hear of these challenges, Enhertu, like many ADCs gaining approval, addresses an unmet need for patients with advanced disease who have no strong alternative options.
Or read this on Hacker News
